Orthometrix, Inc. (OMRX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Orthometrix, Inc. (OMRX) trades at $0.0001 with AI Score 59/100 (Grade B). Orthometrix, Inc. specializes in developing and marketing technologies aimed at improving musculoskeletal mobility and treating related pain. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for OMRX: OMRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OMRX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OMRX: 1/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Orthometrix, Inc. (OMRX) Healthcare & Pipeline Overview
Orthometrix, Inc. focuses on musculoskeletal health, providing diagnostic and therapeutic solutions across healthcare, veterinary, and sports sectors. Its patented technologies in bone measurement, rehabilitation, and pain management position it within the niche medical specialties market, serving diverse customer segments globally.
What Is the Investment Thesis for OMRX?
Orthometrix, Inc. presents a focused investment opportunity within the medical specialties sector, driven by its proprietary technologies in musculoskeletal diagnostics and therapeutics. The company's gross margin of 69.6% indicates strong pricing power and efficient cost management. A key value driver is the increasing demand for non-invasive pain management solutions and rehabilitation technologies, particularly for conditions like osteoarthritis and plantar fasciitis. Growth catalysts include expanding the market reach of its ESWT systems and leveraging its patented vibration technology in new applications. However, the company's small market capitalization and OTC listing introduce liquidity and regulatory risks. The high beta of -51.49 suggests extreme volatility relative to the market. While the profit margin of 27.2% is attractive, investors should carefully assess the sustainability of these earnings given the competitive landscape and the company's limited resources.
Based on FMP financials and quantitative analysis
OMRX Key Highlights
Gross margin of 69.6% indicates strong profitability in its product offerings.
- Profit margin of 27.2% demonstrates efficient cost management and revenue generation.
- Beta of -51.49 suggests the stock price moves inversely and with greater volatility compared to the overall market.
- The company serves diverse markets including healthcare, veterinary, and sports/fitness, providing multiple revenue streams.
- Specializes in non-invasive technologies to treat musculoskeletal conditions, aligning with the growing demand for less invasive treatments.
Who Are OMRX's Competitors?
OMRX is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIXF Acarix AB (publ) | $0.03 | +0.00% | $31.5M | 52 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.1M | 53 |
| EBRCZ EBR Systems, Inc. | $0.21 | -11.02% | $134M | 45 |
| SI SHOULDER INNOVATIONS, INC. | $23.26 | +10.08% | $482M | 30 |
| AVNBF Avon Technologies Plc | $22.49 | +0.00% | $662M | 38 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| BMXXY bioMérieux S.A. | $8.56 | +7.81% | $10.1B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OMRX's Key Strengths?
Proprietary technologies in bone and muscle measurement.
- Diverse customer base across healthcare, veterinary, and sports markets.
- High gross profit margin.
- Established presence in the musculoskeletal health market.
What Are OMRX's Weaknesses?
Small market capitalization and limited financial resources.
- OTC listing increases liquidity and regulatory risks.
- High beta indicates significant stock price volatility.
- Limited brand recognition compared to larger competitors.
What Could Drive OMRX Stock Higher?
Increasing demand for non-invasive pain management solutions, driving adoption of ESWT systems.
- Growing awareness of musculoskeletal health and the need for diagnostic and rehabilitation technologies.
- Potential partnerships with sports teams and fitness centers to expand market reach.
- Development and launch of new home-based rehabilitation products.
- Expansion into international markets, particularly in Europe and Asia.
What Are the Key Risks for OMRX?
Negative return on equity (-15.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device companies with greater resources.
- Regulatory changes affecting the approval and reimbursement of medical devices.
- Technological obsolescence of existing products.
- Limited liquidity due to OTC listing and low trading volume.
- Dependence on key personnel and limited management depth.
What Are the Growth Opportunities for OMRX?
- Expansion of Extracorporeal Shock Wave Therapy (ESWT) Systems: The market for ESWT is projected to grow as non-invasive pain management becomes more prevalent. Orthometrix can capitalize on this trend by expanding the distribution and marketing of its ESWT systems, targeting podiatrists, orthopedic surgeons, and physical therapists. The global ESWT market is expected to reach $257.8 million by 2028, presenting a substantial growth opportunity for Orthometrix.
- Penetration of the Veterinary Market: Orthometrix's bone and muscle diagnostic systems and rehabilitation technologies have applications in the veterinary market, particularly for treating musculoskeletal conditions in animals. By focusing on veterinary clinics and animal hospitals, Orthometrix can tap into a growing market driven by increasing pet ownership and spending on pet healthcare. The veterinary healthcare market is projected to reach $46.3 billion by 2027.
- Development of Home-Based Rehabilitation Solutions: The demand for home-based rehabilitation is increasing, driven by factors such as an aging population and the desire for convenient and cost-effective healthcare solutions. Orthometrix can develop and market home-use versions of its motorized exercise systems and human performance measurement systems, targeting individuals recovering from injuries or managing chronic conditions. The global home healthcare market is expected to reach $365.2 billion by 2028.
- Strategic Partnerships with Sports Teams and Fitness Centers: Orthometrix can establish partnerships with professional sports teams, fitness centers, and gyms to promote its rehabilitation and human performance measurement systems. These partnerships can provide access to a large customer base and enhance brand awareness.
- International Market Expansion: Orthometrix currently serves markets in the United States and internationally. Expanding its presence in key international markets, such as Europe and Asia, can drive revenue growth. This expansion could involve establishing distribution agreements, opening regional offices, or acquiring local companies. The global medical device market is expected to reach $603.4 billion by 2028, highlighting the potential for international growth.
What Are OMRX's Competitive Advantages?
- Patented Technologies: Orthometrix holds patents for its motorized exercise systems and vibration technology, providing a competitive advantage.
- Specialized Expertise: The company has deep expertise in musculoskeletal diagnostics and therapeutics, built over several decades.
- Established Customer Base: Orthometrix has a loyal customer base in the healthcare, veterinary, and sports/fitness markets.
- Integrated Product Portfolio: The company offers a comprehensive range of products and services for bone and muscle health.
What Does OMRX Do?
Founded in 1993 and headquartered in Naples, Florida, Orthometrix, Inc., formerly known as Norland Medical Systems, Inc., has evolved into a developer and marketer of technologies designed to enhance musculoskeletal mobility and alleviate associated pain. The company's portfolio includes peripheral quantitative computed tomography (pQCT) bone and muscle measurement systems used in research and clinical settings. These systems provide detailed assessments of bone density and muscle mass, aiding in the diagnosis and monitoring of conditions like osteoporosis and sarcopenia. Orthometrix also offers patented motorized exercise systems incorporating vibration technology, targeting rehabilitation, physical therapy, and sports medicine applications. These systems are designed to improve muscle strength, flexibility, and overall physical performance. Additionally, the company provides human performance measurement systems for tracking progress in power and mobility, as well as extracorporeal shock wave therapy (ESWT) systems for non-invasive pain management, particularly for plantar fasciitis. Orthometrix serves a diverse clientele, including healthcare providers, veterinary clinics, sports teams, fitness centers, and individual consumers. The company markets its products and services both domestically and internationally, focusing on delivering innovative solutions for musculoskeletal health and pain management.
What Products and Services Does OMRX Offer?
- Develops peripheral quantitative computed tomography (pQCT) bone and muscle measurement systems.
- Markets and services pQCT systems for research and clinical applications.
- Offers patented motorized exercise systems for rehabilitation, physical therapy, and sports medicine.
- Provides human performance measurement systems for monitoring improvement in power and mobility.
- Markets and services extracorporeal shock wave therapy (ESWT) systems for pain management.
- Sells patented motorized exercise systems to professional teams, fitness centers, and the general public.
How Does OMRX Make Money?
- Sales of diagnostic and therapeutic medical devices to healthcare providers and research institutions.
- Service and maintenance contracts for its installed base of medical equipment.
- Direct sales of rehabilitation and fitness equipment to consumers.
- Partnerships with sports teams and fitness centers for product distribution and marketing.
What Industry Does OMRX Operate In?
Orthometrix, Inc. operates within the medical specialties industry, which is characterized by rapid technological advancements and increasing demand for minimally invasive procedures. The market for musculoskeletal diagnostic and therapeutic devices is driven by an aging population, rising obesity rates, and growing awareness of sports-related injuries. Competitors include companies like ACBM (AccuBioTech Medical), ARYX (ARYx Therapeutics), AXMP (Advanced Medical Payment), HDVY (Hardevy), and IBXG (IBio), each with varying focuses within the broader medical device landscape. Orthometrix differentiates itself through its patented vibration technology and integrated approach to bone and muscle health.
Who Are OMRX's Key Customers?
- Hospitals and clinics using bone and muscle measurement systems for diagnostics.
- Research institutions conducting studies on bone and muscle health.
- Physical therapy centers and rehabilitation clinics using motorized exercise systems.
- Sports teams and athletes using performance measurement and rehabilitation equipment.
- Individual consumers purchasing home-use fitness and rehabilitation products.
Company Profile
Orthometrix, Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Naples, US. The company is led by CEO Reynald G. Bonmati. OMRX has traded publicly since 1995.
Financial Health
Orthometrix, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Orthometrix, Inc. stands at -15.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 51.4%, showing how much profit it generates from its asset base. OMRX trades at a trailing price-to-earnings ratio of 0.01, below the Healthcare sector average of ~23x. A current ratio of 5.35 indicates the company holds enough short-term assets to cover its near-term obligations.
OMRX Valuation & Market Position
Relative to its peer group, OMRX's quantitative score of 59/100 is above the peer average of 44/100.
OMRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary technologies in bone and muscle measurement.
- Diverse customer base across healthcare, veterinary, and sports markets.
- High gross profit margin.
- Established presence in the musculoskeletal health market.
Bear Case
- Small market capitalization and limited financial resources.
- OTC listing increases liquidity and regulatory risks.
- High beta indicates significant stock price volatility.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OMRX Latest News
No recent news available for OMRX.
OMRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OMRX.
Price Targets
Wall Street price target analysis for OMRX.
OMRX MoonshotScore
What does this score mean?
The MoonshotScore rates OMRX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Reynald G. Bonmati
Managing Director
Reynald G. Bonmati serves as the Managing Director of Orthometrix, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing small teams and guiding the company's focus on musculoskeletal mobility technologies. Bonmati is responsible for the overall performance of Orthometrix, including product development, marketing, and sales. He manages a team of 7 employees.
Track Record: Under Bonmati's leadership, Orthometrix has continued to develop and market its core product lines, including bone and muscle measurement systems and rehabilitation technologies. He has focused on serving healthcare, veterinary, and sports/fitness markets. Specific milestones and achievements during his tenure are not detailed in the provided data.
OMRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orthometrix, Inc. may not meet minimum financial standards or reporting requirements to be listed on higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Investing in companies on the OTC Other tier carries significantly higher risks compared to those listed on regulated exchanges due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and financial reporting requirements.
- Higher potential for fraud and manipulation.
- Greater price volatility compared to exchange-listed stocks.
- Limited access to company information and management.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's revenue sources and customer base.
- Understand the company's capital structure and debt obligations.
- Consult with a financial advisor before investing.
- The company has been in operation since 1993.
- Orthometrix possesses patented technologies.
- The company serves diverse markets including healthcare, veterinary, and sports/fitness.
- Orthometrix has a functional website and contact information.
OMRX Healthcare Stock FAQ
What does the AI Score mean for OMRX?
OMRX holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Orthometrix, Inc. specializes in developing and marketing technologies aimed at improving musculoskeletal mobility and treating related pain. The company offers a range of diagnostic …
What does Orthometrix, Inc. do?
Orthometrix, Inc. develops, markets, and services technologies focused on improving musculoskeletal mobility and treating related pain. Their product line includes peripheral quantitative computed tomography (pQCT) bone and muscle measurement systems for research and clinical applications, patented motorized exercise systems for rehabilitation, and extracorporeal shock wave therapy (ESWT) systems for non-invasive pain treatment.
What are the main risks for OMRX?
Orthometrix, Inc. faces several risks, including competition from larger medical device companies, regulatory changes affecting medical device approvals, potential technological obsolescence, and limited liquidity due to its OTC listing. The company's small size and limited financial resources may also constrain its ability to invest in research and development, marketing, and international expansion. Investors should carefully consider these risks before investing in OMRX.
What are the key factors to evaluate for OMRX?
Orthometrix, Inc. (OMRX) holds an AI score of 59/100 (moderate). presents a focused investment opportunity within the medical specialties sector, driven by its proprietary technologies in musculoskeletal diagnostics and therapeutics. Not financial advice.
How frequently does OMRX data refresh on this page?
OMRX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OMRX's recent stock price performance?
Orthometrix, Inc. (OMRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technologies in bone and muscle measurement. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OMRX overvalued or undervalued right now?
Orthometrix, Inc. (OMRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OMRX before investing?
Before investing in Orthometrix, Inc. (OMRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OMRX to a portfolio?
Key strength of Orthometrix, Inc. (OMRX): Proprietary technologies in bone and muscle measurement. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for OMRX.
- OTC market data may be less reliable than exchange-listed data.